Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Hansa Biopharma : announces participation in Fall conferences and an updated financial calendar

08/31/2020 | 02:01am EST

Hansa Biopharma has been invited to participate in several leading global healthcare conferences during the Fall 2020. 
Hansa Biopharma will host a Capital Markets Day event on October 29, 2020 in Copenhagen as a combined virtual/physical setup. 

Lund, SwedenAugust 31, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will present at the following upcoming investor conferences in September:

· Pareto Securities Health Care Conference on Thursday September 3, 2020, at 15:30 CET
· Citibank's Annual BioPharma Virtual Conference on Wednesday September 9, 2020 
· H.C.Wainwrigth Healthcare Conference on Tuesday September 15, 2020 
· Bank of America Merill Lynch Healthcare Conference on Wednesday September 16, 2020
· MorganStanley Global Healthcare Conference on Friday September 18, 2020 at 8:00am EST/14:00 CET
· ABG Small & Midcap Seminar, Copenhagen on Wednesday September 23, 2020 at 13:30 CET

A link to the presentations and webcasts will be available on the Events & Presentations page of the Company's website at http://www.hansabiopharma.com (http://www.hansabiopharma.com.).

Calendar
Aug 31,2020       Kempen Road Show, Tel Aviv/Paris/Benelux (virtual)
Sep 3, 2020        Pareto Healthcare Conference, Stockholm (virtual)
Sep 9, 2020        Citibank's Annual BioPharma Virtual Conference, Boston (virtual)
Sep 15, 2020      H.C. Wainwright Healthcare Conference, NYC (virtual)
Sep 16, 2020      Bank of America Merill Lynch Healthcare Conf., London (virtual)
Sep 18, 2020      MorganStanley Global Healthcare Conference, NYC (virtual)
Sep 23, 2020      ABG Small & Mid Cap Seminar, Copenhagen and virtual
Oct 22, 2020       Interim Report Jan-Sep 2020
Oct 29, 2020       Hansa Biopharma Capital Markets Day, Copenhagen and virtual
Nov 17, 2020      Bryan Garnier Healthcare Conference, Paris
Nov 18, 2020      Jefferies Healthcare Conference, London
Nov 25, 2020      Ökonomisk Ugebrev Life Science Conference, Copenhagen
Feb 2, 2021        Interim report for Jan - Dec 2020
April 8, 2021       Annual Report 2020
April 22, 2021     Interim report for Jan - Mar 2021
July 15, 2021      Interim report for Jan - Jun 2021
Oct 21, 2021       Interim report for Jan - Sep 2021

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company's lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-announces-participation-in-fall-conferences-and-an-updated-financial-calendar,c3182962

https://mb.cision.com/Main/1219/3182962/1298637.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
HANSA BIOPHARMA AB (PUBL) -0.71% 183.5 Delayed Quote.-23.46%
HANSAE YES24 HOLDINGS CO., LTD 2.79% 7380 End-of-day quote.-3.66%
All news about HANSA BIOPHARMA AB (PUBL)
01/11HANSA BIOPHARMA : Forecasts FY20 Operating Loss to Widen
MT
01/11HANSA BIOPHARMA : provides business update incl. certain key financials ahead of..
AQ
2020HANSA BIOPHARMA :  Biopharma to present at the 39th Annual J.P. Morgan Healthcar..
AQ
2020HANSA BIOPHARMA : Nomination Committee formed
AQ
2020Hansa Biopharma interim report Jan-Sep 2020
AQ
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
PU
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
AQ
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
PU
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
AQ
2020HANSA BIOPHARMA : certified as a Great Place to Work
AQ
More news
Financials
Sales 2020 35,8 M 4,31 M 4,31 M
Net income 2020 -396 M -47,7 M -47,7 M
Net cash 2020 1 385 M 167 M 167 M
P/E ratio 2020 -19,6x
Yield 2020 -
Capitalization 8 183 M 980 M 985 M
EV / Sales 2020 190x
EV / Sales 2021 74,4x
Nbr of Employees 80
Free-Float 95,9%
Chart HANSA BIOPHARMA AB (PUBL)
Duration : Period :
Hansa Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANSA BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 295,67 SEK
Last Close Price 184,00 SEK
Spread / Highest target 123%
Spread / Average Target 60,7%
Spread / Lowest Target 3,26%
EPS Revisions
Managers and Directors
NameTitle
Søren Tulstrup President & Chief Executive Officer
Ulf Arne Wiinberg Chairman
Christian Kjellman Chief Operating & Scientific Officer
Donato Spota Chief Financial Officer
Achim Kaufhold Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HANSA BIOPHARMA AB (PUBL)-23.46%980
MODERNA, INC.19.79%49 519
LONZA GROUP AG4.32%49 499
CELLTRION, INC.-13.37%38 562
IQVIA HOLDINGS INC.6.35%36 531
SEAGEN INC.8.94%34 515